{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:24:47Z","timestamp":1787225087898,"version":"build-2736575974"},"reference-count":5,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Nemolizumab, a humanized IgG2 monoclonal antibody that inhibits interleukin (IL)-31 signalling by binding to the IL-31 receptor alpha (IL-31 RA) and a first-in-class IL-31 RA antagonist, has proven effective at reducing pruritus and objective skin signs in atopic dermatitis and nodular prurigo. However, by suppressing itch, nemolizumab may also delay the presentation of pruritic skin conditions such as scabies, potentially complicating the diagnosis. This case highlights a patient who developed a late presentation of scabies while on long-term nemolizumab therapy. The delayed pruritic response to scabies, likely due to the suppression of itch by nemolizumab, underscores the need for thorough dermatological evaluation.<\/jats:p>","DOI":"10.1093\/ced\/llag309","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:38:58Z","timestamp":1784374738000},"source":"Crossref","is-referenced-by-count":0,"title":["Apruritic scabies presenting on interleukin-31 blockade with nemolizumab: a case report"],"prefix":"10.1093","author":[{"given":"Bindi","family":"Gaglani","sequence":"first","affiliation":[{"name":"St John\u2019s Institute of Dermatology , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Agius","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H","family":"Smith","sequence":"additional","affiliation":[{"name":"Guy\u2019s and St Thomas\u2019 Hospitals NHS Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Woolf","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E","family":"Pink","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"2026082006313568100_llag309-B1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11882-014-0423-y","article-title":"Interleukin-31: a novel diagnostic marker of allergic diseases","volume":"14","author":"Rabenhorst","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"key":"2026082006313568100_llag309-B2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","article-title":"Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase 3 trial","volume":"161","author":"St\u00e4nder","year":"2025","journal-title":"JAMA Dermatol"},{"key":"2026082006313568100_llag309-B3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"key":"2026082006313568100_llag309-B4","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/all.13870","article-title":"Pruritus in ordinary scabies: IL-31 from macrophages induced by overexpression of thymic stromal lymphopoietin and periostin","volume":"74","author":"Hashimoto","year":"2019","journal-title":"Allergy"},{"key":"2026082006313568100_llag309-B5","author":"British Association of Dermatologists"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag309\/69648682\/llag309.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag309\/69648682\/llag309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:31:43Z","timestamp":1787221903000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/advance-article\/doi\/10.1093\/ced\/llag309\/8738662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":5,"URL":"https:\/\/doi.org\/10.1093\/ced\/llag309","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"llag309"}}